Literature DB >> 2502679

Recent advances in the understanding, diagnosis and treatment of primary hyperoxaluria type 1.

C J Danpure1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2502679     DOI： 10.1007/bf01800727

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  76 in total

Review 1.  VITAMIN B6 AND OXALATE METABOLISM.

Authors:  S N GERSHOFF
Journal:  Vitam Horm       Date:  1964       Impact factor: 3.421

2.  Clinical manifestations of primary hyperoxaluria.

Authors:  E G HALL; E F SCOWEN; R W WATTS
Journal:  Arch Dis Child       Date:  1960-02       Impact factor: 3.791

3.  Primary hyperoxaluria.

Authors:  H E ARCHER; A E DORMER; E F SCOWEN; R W WATTS
Journal:  Lancet       Date:  1957-08-17       Impact factor: 79.321

4.  Observations on the possible genetic basis of primary hyperoxaluria.

Authors:  H E ARCHER; A E DORMER; E F SCOWEN; R W WATTS
Journal:  Ann Hum Genet       Date:  1958-07       Impact factor: 1.670

5.  Hemodialysis for oxaluric renal failure.

Authors:  A Saxon
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

6.  Glyoxylate metabolism by isolated rat liver peroxisomes.

Authors:  S L Vandor; N E Tolbert
Journal:  Biochim Biophys Acta       Date:  1970-09-22

7.  Failure of renal transplantation in primary oxalosis.

Authors:  J Klauwers; P L Wolf; R Cohn
Journal:  JAMA       Date:  1969-07-28       Impact factor: 56.272

8.  Carboligase activity of alpha-ketoglutarate dehydrogenase.

Authors:  M A Schlossberg; R J Bloom; D A Richert; W W Westerfeld
Journal:  Biochemistry       Date:  1970-03-03       Impact factor: 3.162

9.  Mitochondrial damage and the subcellular distribution of 2-oxoglutarate:glyoxylate carboligase in normal human and rat liver and in the liver of a patient with primary hyperoxaluria type I.

Authors:  C J Danpure; P Purkiss; P R Jennings; R W Watts
Journal:  Clin Sci (Lond)       Date:  1986-05       Impact factor: 6.124

10.  Immunocytochemical localization of human hepatic alanine: glyoxylate aminotransferase in control subjects and patients with primary hyperoxaluria type 1.

Authors:  P J Cooper; C J Danpure; P J Wise; K M Guttridge
Journal:  J Histochem Cytochem       Date:  1988-10       Impact factor: 2.479
View more
  7 in total

1.  Orthotopic liver transplantation in liver-based metabolic disorders.

Authors:  A P Mowat
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

2.  Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT).

Authors:  A C Tarn; C von Schnakenburg; G Rumsby
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

3.  Excessive urinary oxalate excretion after combined renal and hepatic transplantation for correction of hyperoxaluria type 1.

Authors:  H Ruder; G Otto; R B Schutgens; U Querfeld; R J Wanders; K H Herzog; P Wölfel; S Pomer; K Schärer; G A Rose
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

4.  Clinical quiz. Primary hyperoxaluria (PH) type 1.

Authors:  S Rinaldi; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

Review 5.  Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity.

Authors:  C J Danpure; P R Jennings; P Fryer; P E Purdue; J Allsop
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Cytosolic compartmentalization of hepatic alanine:glyoxylate aminotransferase in patients with aberrant peroxisomal biogenesis and its effect on oxalate metabolism.

Authors:  C J Danpure; P Fryer; S Griffiths; K M Guttridge; P R Jennings; J Allsop; A B Moser; S Naidu; H W Moser; M MacCollin
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 7.  Treatment of inherited metabolic disorders by liver transplantation.

Authors:  M Burdelski; B Rodeck; A Latta; K Latta; J Brodehl; B Ringe; R Pichlmayr
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.